Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Fibrate Drugs Market Heading Into 2029?

The market size for fibrate drugs has witnessed steady growth in the past few years. From $3.49 billion in 2024, it’s projected to reach $3.58 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.8%. The historic growth trend is linked to factors such as the rise in lipid management, focus on cholesterol management, increased clinical research and trials, attention towards reducing cardiovascular risks, and the use of combination therapies.

The market size for fibrate drugs is predicted to experience significant expansion in the coming years. It’s expected to rise to $4.72 billion by 2029, with a compound annual growth rate (CAGR) of 7.2%. The projection for growth in this period is due to factors such as changing treatment guidelines, emphasis on residual risk, progress in precision medicine, and advances in drug delivery. Notable trends for this period include alternative drug formulations, embracing telemedicine, the use of fibrates among high-risk groups, efforts to control triglyceride levels, and an increased focus on HDL level enhancement.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11932&type=smp

Which Factors Are Pushing The Fibrate Drugs Market Forward?

The rise in cases of heart-related disorders is projected to fuel the expansion of the fibrate drug market. These disorders incorporate a variety of conditions impacting the heart and blood vessels, including coronary heart disease, congenital heart disease, and others. Fibrates are used in treating patients who are at high risk of further heart attacks and strokes due to existing ailments in their circulatory system, thereby enhancing the growth of the fibrate drug market. For instance, the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, reported that in May 2024, ischemic heart diseases led to 5,302 deaths, a slight rise from 5,290 deaths in 2022. Moreover, the overall number of fatalities due to hypertensive diseases amounted to 3.7% in 2022, an increase from 3.4% in 2021. Consequently, the escalating prevalence of cardiac diseases is stimulating the growth of the fibrate drugs market.

Which Segment Held The Largest Share In The Fibrate Drugs Market In 2025?

The fibrate drugs market covered in this report is segmented –

1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs

2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Clofibrate: Standard Clofibrate, Combination Products

2) By Fenofibrates: Fenofibrate Capsules, Fenofibrate Tablets, Combination Products

3) By Fenofibric Acids: Fenofibric Acid Capsules, Combination Products

4) By Gemfibrozil: Standard Gemfibrozil, Combination Products

5) By Other Drugs: Other Fibrate Formulations, Emerging Fibrate Drugs

How Are Key Trends Driving Expansion In The Fibrate Drugs Industry?

Leading companies in the fibrate drugs market are strategizing to maintain their market position by investing in the creation of innovative solutions such as fixed-dose combinations. Fixed-dose combinations are pharmaceutical concoctions that consist of two or more active ingredients administered in a single dosage, which provide convenience in their use and potentially lead to better therapeutic results. As an exemplar, in May 2023, Intercept Pharmaceuticals Inc., a biopharmaceutical company based in the U.S., was granted approval by the U.S. Food and Drug Administration (FDA) for orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate. This combination is a peroxisome proliferator-activated receptor (PPAR) agonist and is under investigation for the potential treatment for primary biliary cholangitis (PBC) patients. OCA, a market product by Intercept known as Ocaliva in the United States, treats PBC, and bezafibrate, a pan-PPAR agonist, has not gained current approval in the U.S. for any therapeutic uses.

Which Organizations Are Driving Progress In The Fibrate Drugs Industry?

Major companies operating in the fibrate drugs market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Bristol-Myers Squibb Co, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Zydus Lifesciences Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd., Natco Pharma, Hetero Drugs Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/fibrate-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Fibrate Drugs Industry?

North America was the largest region in the fibrate drugs market in 2024. The regions covered in the fibrate drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11932&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model